...
首页> 外文期刊>OncoTargets and therapy >Reliability of using circulating tumor cells for detecting epidermal growth factor receptor mutation status in advanced non-small-cell lung cancer patients: a meta-analysis and systematic review
【24h】

Reliability of using circulating tumor cells for detecting epidermal growth factor receptor mutation status in advanced non-small-cell lung cancer patients: a meta-analysis and systematic review

机译:使用循环肿瘤细胞检测表皮生长因子受体突变状态在晚期非小细胞肺癌患者中的可靠性:META分析和系统评论

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Purpose: To evaluate the clinical value of circulating tumor cells as a surrogate to detect epidermal growth factor receptor mutation in advanced non-small-cell lung cancer (NSCLC) patients. Methods: We searched the electronic databases, and all articles meeting predetermined selection criteria were included in this study. The pooled sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio were calculated. The evaluation indexes of the diagnostic performance were the summary receiver operating characteristic curve and area under the summary receiver operating characteristic curve. Results: Eight eligible publications with 255 advanced NSCLC patients were included in this meta-analysis. Taking tumor tissues as reference, the pooled sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio of circulating tumor cells for detecting the epidermal growth factor receptor mutation status were found to be 0.82 (95% confidence interval [CI]: 0.50–0.95), 0.95 (95% CI: 0.24–1.00), 16.81 (95% CI: 0.33–848.62), 0.19 (95% CI: 0.06–0.64), and 86.81 (95% CI: 1.22–6,154.15), respectively. The area under the summary receiver operating characteristic curve was 0.92 (95% CI: 0.89–0.94). The subgroup analysis showed that the factors of blood volume, histological type, EGFR-tyrosine kinase inhibitor therapy, and circulating tumor cell and tissue test methods for EGFR accounted for the significant difference of the pooled specificity. No significant difference was found between the pooled sensitivity of the subgroup. Conclusion: Our meta-analysis confirmed that circulating tumor cells are a good surrogate for detecting epidermal growth factor receptor mutation when tumor tissue is unavailable in advanced NSCLC patients, but more precise techniques are needed to improve their clinical efficiency.
机译:目的:评估循环肿瘤细胞作为替代品检测先进非小细胞肺癌(NSCLC)患者表皮生长因子受体突变的临床价值。方法:我们搜索了电子数据库,并在本研究中包含满足预定选择标准的所有文章。计算汇集的敏感性,特异性,正似然比,负似然比和诊断量比。诊断性能的评估指标是汇总接收器操作特性曲线和区域下的概要接收器操作特性曲线。结果:八个符合条件的出版物,255名高级NSCLC患者均包含在该荟萃分析中。将肿瘤组织作为参考,循环肿瘤细胞用于检测表皮生长因子受体突变状态的汇集性,特异性,阳性似然比,负似然比和诊断差异比例为0.82(95%置信区间[CI] :0.50-0.95),0.95(95%CI:0.24-1.00),16.81(95%CI:0.33-848.62),0.19(95%CI:0.06-0.64)和86.81(95%CI:1.22-6,154.15) , 分别。总结接收器操作特征曲线下的区域为0.92(95%CI:0.89-0.94)。亚组分析表明,血容量,组织学型,EGFR-酪氨酸激酶抑制剂治疗的因素,以及EGFR的循环肿瘤细胞和组织试验方法占汇集特异性的显着差异。在亚组的汇总敏感性之间没有发现显着差异。结论:我们的荟萃分析证实,当肿瘤组织在先进的NSCLC患者中不可用时,循环肿瘤细胞是检测表皮生长因子受体突变的良好替代物,但需要更精确的技术来提高其临床效率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号